title: Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy.
abstract: Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if > or = 10 pg/ml. We identified 69 patients with median age of 34 years (range 16 - 74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and beta2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P < 0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.
authors.affiliation: Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, USA.
authors.forename: Carlo
authors.initials: C
authors.lastname: Visco
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Vassilakopoulos
authors.forename: Kay Oliver
authors.initials: KO
authors.lastname: Kliche
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Nadali
authors.forename: Simonetta
authors.initials: S
authors.lastname: Viviani
authors.forename: Valeria
authors.initials: V
authors.lastname: Bonfante
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: P
authors.initials: P
authors.lastname: Notti
authors.forename: George Z
authors.initials: GZ
authors.lastname: Rassidakis
authors.forename: Prema
authors.initials: P
authors.lastname: Peethambaram
authors.forename: Richard
authors.initials: R
authors.lastname: Wilder
authors.forename: Thomas
authors.initials: T
authors.lastname: Witzig
authors.forename: Massimo
authors.initials: M
authors.lastname: Gianni
authors.forename: Gianni
authors.initials: G
authors.lastname: Bonadonna
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Gerassimos A
authors.initials: GA
authors.lastname: Pangalis
authors.forename: Fernando
authors.initials: F
authors.lastname: Cabanillas
authors.forename: Andreas H
authors.initials: AH
authors.lastname: Sarris
mesh_terms: D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000097:blood; D006689:Hodgkin Disease / Q000097:blood / Q000401:mortality* / Q000532:radiotherapy*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D011878:Radiotherapy; D016019:Survival Analysis; D053482:beta 2-Glycoprotein I
chemical_list: D006023:Glycoproteins; D053482:beta 2-Glycoprotein I; D016753:Interleukin-10